Bernhard K. Keppler , born 1956 in Hockenheim,[1] is a German bioinorganic chemist and physician.

[2] He is dean of the Faculty of chemistry since 2008, head of the inter-university research cluster Translational Cancer Therapy Research (in cooperation with the Medical University of Vienna and Walter Berger [de]) and deputy head of the research network Chemistry, Microbiology and Environmental Systems Science (in cooperation with the Centre for Microbiology and Environmental Systems Science, University of Vienna, Michael Wagner (biologist) [de]).

Keppler is author and co-author of more than 550 papers in peer-reviewed journals, (~20.000 citations, H-index 74), 16 invited reviews, 50 book chapters, and numerous patents.

He is a pioneer in investigating metal-based anticancer drugs and has developed multiple first-in-class compounds including KP1019, KP1339, and KP46 (IT-235, AP-002).

BOLD-100, which is an anticancer drug related to the predecessors molecules KP1339 (NKP-1339, IT-139) and KP1019, is currently being investigated in clinical trials for advanced gastrointestinal cancers in combination with FOLFOX.